Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment.
• Significant challenges hinder CAR T cell efficacy in solid tumors, including antigen heterogeneity, toxicity, poor infiltration, and the immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To review recent engineering strategies aimed at overcoming barriers to CAR T cell therapy in solid tumors.
• To highlight advancements in CAR T cell design for improved safety, specificity, and persistence in the TME.

Main Methods:

• Discussion of affinity-tuned and logic-gated CAR designs for enhanced specificity and reduced off-tumor toxicity.
• Exploration of multi-antigen targeting strategies to combat tumor heterogeneity and antigen escape.
• Review of gene-editing techniques to improve CAR T cell fitness, memory formation, metabolic resilience, and resistance to TME-mediated inhibition.

Main Results:

• Engineering innovations enhance CAR T cell targeting precision and safety profiles.
• Strategies like multi-antigen targeting and gene editing improve CAR T cell infiltration, persistence, and function within the immunosuppressive TME.
• Modified CAR T cells demonstrate improved ability to degrade extracellular matrix and withstand hostile tumor conditions.

Conclusions:

• Advances in rational CAR design and synthetic immunology are paving the way for effective solid tumor CAR T cell therapies.
• Early clinical trials indicate promising outcomes, suggesting the potential for durable and safe responses.
• Continued translational research is crucial to fully realize the therapeutic potential of CAR T cells against solid tumors.